Tempus, Intermountain to collaborate on oncology research

LabPulse.com staff writers
Jun 16, 2022
2019 05 22 19 44 5254 Dna Red Laser 400

Artificial intelligence (AI) developer Tempus and Intermountain Healthcare plan to collaborate on oncology research using genomic testing and data analytics.

Intermountain will use Tempus's solid tumor/normal genomic test, xT, to generate RNA data from existing transcriptomic samples; the RNA data will be matched with DNA data and used for oncology research, according to Tempus.

Latest in Artificial Intelligence
Artificial Intelligence Ai Abstract Social
Techcyte, Mayo Clinic to collaborate on algorithms for pathology platform
March 14, 2023
Artificial Intelligence Ai Hand Social
Alverno Laboratories to expand Ibex’s AI-powered cancer diagnostics suite throughout its Midwest network
March 9, 2023
Artificial Intelligence Lung Color Social
Viz.ai platform to be used in patient enrollment for pulmonary embolism trial
March 6, 2023
Computer Ai Artificial Illustration Social
Guardant NSCLC biomarker test to incorporate Lunit’s AI-based scoring algorithm
February 1, 2023
Related Stories
Sequencing Dna Rna Social
Product Launch
Curio Bioscience emerges from stealth mode with whole-transcriptome spatial mapping kit
Cancer Cell Microenvironment Social
Companion Diagnostics
Tempus, Kartos Therapeutics collaborate on CDx for Merkel cell carcinoma treatment
2019 07 15 18 08 8235 Artificial Intelligence Ai Data 400
Artificial Intelligence
AI algorithm improves accuracy of at-home COVID-19 tests
2019 05 22 19 44 5254 Dna Red Laser 400
Sequencing
Tempus, Eli Lilly collaborate to expand genomic testing
More in Artificial Intelligence
Techcyte, Mayo Clinic to collaborate on algorithms for pathology platform
Techcyte’s Clinical Pathology AI Platform, which is CE-marked under IVDR and designated for research use only in the U.S., imports digital images of liquid-based samples from whole-slide scanners.
March 14, 2023
Artificial Intelligence Ai Abstract Social
Alverno Laboratories to expand Ibex’s AI-powered cancer diagnostics suite throughout its Midwest network
Alverno, among the first U.S. laboratory networks to digitize its pathology services, is also the first to offer the Ibex AI-supported cancer diagnostic service in the U.S.
March 9, 2023
Artificial Intelligence Ai Hand Social
Viz.ai platform to be used in patient enrollment for pulmonary embolism trial
Research institutions participating in the PE-TRACT trial will use the platform, Viz Recruit, to find, screen, and enroll trial candidates.
March 6, 2023
Artificial Intelligence Lung Color Social
Guardant NSCLC biomarker test to incorporate Lunit’s AI-based scoring algorithm
The integrated Lunit Scope PD-L1 algorithm will augment the TissueNext test’s detection of the PD-L1 biomarker in tissue samples using an AI-based scoring system.
February 1, 2023
Computer Ai Artificial Illustration Social
With Bill & Melinda Gates Foundation grant, VisualDx to develop diagnostic, surveillance tools for underserved
The firm said it will use the funds to expand equitable access to its clinical decision support, artificial intelligence, and machine learning tools.
January 18, 2023
Computer Brain Money Social
Paige joins forces with Microsoft on pathology AI
Digital pathology company Paige is partnering with Microsoft on AI technology to develop clinical applications and computational biomarkers for digital pathology images to transform cancer diagnosis and patient care.
January 12, 2023
Artificial Intelligence Ai Hand Social
Most Popular
Quest launches long-COVID testing panels for consumers
Ohio, Kentucky doctors convicted in scheme to bill Medicaid for millions of dollars in unnecessary urinalysis testing
RNA-seq analysis links protein to spread of pancreatic cancer, reveals potential drug target
Point-of-care test developer Proxim Diagnostics obtains strategic investment from BioMérieux
Patients prefer immediate test results, even when the news is bad
Quest Diagnostics offers suite of services for transplant patients and living donors
More in Artificial Intelligence
Avenda Health gets FDA 510(k) clearance for iQuest prostate cancer platform
The iQuest platform provides physicians with a 3D visualization, enabling treatment decisions that consider the extent of the cancer rather than treating the whole organ.
December 8, 2022
Prostate Cancer 3 D Rendering Social
PathomIQ presents data on AI predictive model at SABCS
The model predicts the response to neoadjuvant chemotherapy in patients with triple-negative breast cancer through extracting morphological features.
December 8, 2022
Artificial Intelligence Ai Head Social
Source LDPath, Ibex Medical Analytics ink agreement to deploy AI-enabled pathology platform
AI-enabled tools will be used to diagnose multiple tissue types and improve diagnostic accuracy and efficiency, Source LDPath said.
December 7, 2022
Pathology Digital Workstation Microscope Social
Klick Applied Sciences showcases study data demonstrating AI method for predicting diabetes
Scientists from Klick Applied Sciences are developing a method of predicting diabetes by combining continuous glucose monitor technology with machine-learning models.
December 2, 2022
Diabetes Type 2 Social
PreciseDx, Dordrecht Albert Schweitzer Hospital to evaluate cancer risk stratification platform
The Laboratory of Pathology at Dordrecht, in the Netherlands, will study the performance of PreciseDx's artificial intelligence-based cancer risk stratification platform and test.
November 29, 2022
Pathology Digital Workstation Microscope Social
Deep Bio, Visiopharm collaborate on AI-based digital pathology for prostate cancer diagnosis
The collaboration brings Deep Prostate AI software to Visiopharm’s European diagnostic customers, allowing pathologists to obtain an analysis of whole-slide images of H&E-stained biopsy tissue specimens.
November 15, 2022
Artificial Intelligence Ai Hand Social
Page 1 of 13
Next Page